4Sc Ag

Bayer Intellectual Property Gmbh

Bayer Schering Pharma Ag

Altana Pharma Ag

Bayer Pharma Aktiengesellschaft

Nycomed Gmbh

Matthias Vennemann

Thomas Beckers

Thomas Maier

Thomas Baer

Petra Gimmnich

Astrid Zimmermann

Volker Gekeler

Frank Dullweber

Hemant Joshi

Armin Zülch

Swen Hölder

Gerrit Beneke

Jürgen Braunger

Gudrun Groegor

Ulf Bömer

Hartmut Rehwinkel

Ningshu Liu

Stuart Ince

Thomas Bär

Paola Ciapetti

Jean-Marie Contreras

Florian Dehmel

Uday Joshi

Andreas Strub

Heike Rothfels

Dipak Harel

Mahindra Makhija

Kamlesh Padiya

Juergen Braunger

Thomas Bãr

Ulf BÖMER

Barbara Beckers

Petra Dr Gimmnich

Gianluca Quintini

Compounds of a certain formula (I), in which R1, R2, R3, R4, R5, R6 and R7 have the meanings indicated in the description, are novel effective HDAC inhibitors. 

Sulfonylpyrroles

Fused pyrimidines

Compounds of formula (I) a tautomer or stereoisomer thereof, or a salt thereof, wherein ring B and the pyrimidine to which it is fused, R4, R5, R6 and R7 have the meanings as given in the description and the claims, are effective inhibitors of the Pi3K/Akt pathway.

Fused bicyclic pyrimidines

Compounds of a certain formula I, in which R1, R2, R3, R4, R5 and R6 have the meanings indicated in the description, are effective compounds with anti-proliferative and/or apoptosis inducing activity.

Indolopyridines as Eg5 kinesin modulators

The compounds of formula (I), wherein ring D and ring E together form a fused ring system selected from formula (II), (III), (IV), (V), (VI), (VII), and the salts of these compounds are novel, effective inhibitors of histone deacetylases. 

Tetrahydro-fused pyridines as histone deacetylase inhibitors

Sulphonylpyrroles

Compounds of a certain formula I, in which R1, R2, R3, R4 and X have the meanings indicated in the description, are novel effective compounds with Eg5 inhibitory, anti-proliferative and/or apoptosis inducing activity.

Benzothienopyridines for use as inhibitors of Eg5 kinesin

Compounds of the formula I in which the substitutents have the definitions provided in the specification, are novel, effective HDAC inhibitors.

Compounds of the formula (1) in which R1, R2, R3, R4 and X have the meanings indicated in the description, are novel effective compounds with Eg5 inhibitory, anti-proliferative and/or apoptosis inducing activity.

Growing community of inventors

Constance, Germany

Matthias Vennemann